Eucure Bio Starts China Trial of CTLA4 Treatment for Solid Tumors

Eucure Biopharma, the Beijing immunotherapy subsidiary of Biocytogen, started a China Phase I trial of its anti-CTLA4 mAb in patients with solid tumors. In 2020, Eucure completed an Australian Phase I dose-escalation trial of the candidate, where it demonstrated acceptable safety. Eucure has developed a pipeline of more than ten candidates, two of which have been approved to start clinical trials in the US and China . Its parent, Biocytogen, is a China animal models CRO. More details.... Share this with colleagues: // //